FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
BLA FilingapprovedLeqembi IqlikPositive
AI Analysis
Summary
FDA approves Eisai's Leqembi Iqlik (lecanemab-irmb) subcutaneous injection for early Alzheimer's disease through a supplemental BLA, expanding the treatment's formulation options.
Outcome Details
FDA approved supplemental Biologics License Application (sBLA) for once weekly lecanemab-irmb subcutaneous injection as a starting dose
Importance:8/10
Sentiment:
0.90
FDA ApprovalBiologics License ApplicationSubcutaneous InjectionAlzheimer's DiseaseSupplemental BLA
Related Companies
Read the original article
Published by PR Newswire Biotech on July 14, 2026 2:42 AM